Gene tests may protect older breast cancer patients from other tumors
A significant number of older women with breast cancer may have genetic mutations that put them at risk of additional cancers, particularly ovarian cancer, a new study finds.
A small number of older women with breast cancer, a new study shows, may have genetic mutations that put them at risk for additional cancers , particularly ovarian cancer.
The researchers said that as many as one in 40 postmenopausal women with breast cancer before age 65 has a mutation in the BRCA1 or BRCA2 genes.
The researchers said that there is a mutation in the BRCA1 or BRCA2 genes in as many as one in 40 postmenopausal women with breast cancer before age 65.
Currently, the guidelines emphasize genetic testing in women who have a strong family history of these mutations. A well-publicized risk group is women of Ashkenazi Jewish descent. These women face about a 2.5 percent increased risk of having these mutations, study author Dr. Allison Kurian said.
The recommendations are now emphasizing genetic testing of people who have a deep family history of such mutations. Women of Ashkenazi Jewish origin are a well-publicised risk category. Such people face an increased risk of getting such mutations around 2.5 per cent, the author of the study Dr. Allison Kurian said.
"Most women survive breast cancer, and a healthy woman may live quite a while after breast cancer treatment. Could this person get breast cancer again? What about ovarian cancer? I think this risk should be discussed with them," Kurian said. She's an associate professor of medicine and epidemiology and population health at Stanford University, in California.
"Many women survive breast cancer, and after breast cancer treatment a healthy patient can live for quite a while. Will this person get breast cancer again? How about ovarian cancer? I think this possibility should be addressed with them," Kurian said. She is an associate professor at Stanford University, California, in medicine and epidemiology, and public health.
"We found the likelihood of carrying a BRCA mutation was about 2.5 percent in postmenopausal women diagnosed with breast cancer when they were under 65," she noted.
"In postmenopausal women diagnosed with breast cancer when they were under 65, we found the risk of having a BRCA mutation was around 2.5 per cent," she said.
When the investigators included older women diagnosed with breast cancer, there was a 3.5 percent risk of a BRCA or other mutation in the group.
If the study examined older women diagnosed with breast cancer, the population had a 3.5 per cent chance of BRCA or other mutation.
Funding was provided by Myriad Genetics, the Suzanne Pride Bryan Fund for Breast Cancer Research, the Jan Weimer Faculty Chair in Breast Oncology, and the BRCA Foundation. Myriad Genetics makes the genetic tests.
Myriad Genetics, the Suzanne Pride Bryan Breast Cancer Research Program, the Jan Weimer Faculty Chair of Breast Oncology and the BRCA Foundation provided funding. Myriad Genetics do the genetic research.
Kurian said in addition to family history, doctors often take age into account when deciding whether or not to suggest genetic testing.
In addition to family history, Kurian said doctors also take the age into consideration when determining whether to consider genetic testing or not.
The study included previously collected data on nearly 162,000 women between 1993 and 1998. The women were aged 50 to 79, and were from all over the United States.
Previously, the research contained data gathered on almost 162,000 women between 1993 and 1998. The women were between the ages of 50 and 79, and came from all over the USA.
From that larger group of women, the researchers compared nearly 2,200 women who were diagnosed with breast cancer to just over 2,300 women without the disease. The average age of women with a breast cancer diagnosis was 73.
The researchers compared approximately 2,200 women diagnosed with breast cancer to just over 2,300 women without the disease, from the broader group of people. The mean age of women diagnosed with breast cancer was 73.
In the whole breast cancer group, the researchers found a 3.5 percent genetic mutatlon rate. Just 1.3 percent of women without breast cancer had the genetic mutations, the findings showed.
The researchers found a genetic mutatlon prevalence of 3.5 per cent in the entire breast cancer population. The findings showed that only 1.3 per cent of women without breast cancer had the genetic mutations.
Only about one-third of the women who had breast cancer and were found to have BRCA mutations had been recommended for genetic testing. In the women without cancer, but who had a BRCA mutation, only one in five had been recommended by their doctor for genetic testing.
With genetic testing, only about one third of the women who had breast cancer and who were found to have BRCA mutations were recommended. Just one in five had been recommended by their doctor for genetic testing in the women without cancer but who had a BRCA mutation.
Robert Smith, the senior vice president for cancer screening at the American Cancer Society, said this was an interesting study that suggests there may be value in testing this older group of women who've already had breast cancer.
Robert Smith, the senior vice president at the American Cancer Society for cancer screening, said this was an interesting study that shows that there may be benefit in studying this older group of women who have already had breast cancer.
"The guideline-developing groups will look at this information to help inform their recommendations. This study will have to be put into context with other studies, but this data suggests this (genetic testing in postmenopausal women with breast cancer) is something to consider," Smith said.
"This research will be looked at by the guideline-developing organizations to better inform their guidelines, and will need to be placed into context with other studies, but this evidence indicates this (genetic testing of postmenopausal women with breast cancer) is something to consider," Smith said.
Kurian said the test isn't expensive.
She said the usual out-of-pocket cost for someone with insurance is about $100. For women without insurance, she said the cost is about $250 or less.
Kurian did not say the test was costly.
She said the average out-of-pocket expense is about $100 for those with insurance. She said the cost to women without insurance is about $250 or less.
The study was published March 10 in the Journal of the American Medical Association.
When/How Often to Get Breast Cancer Screenings/Mammograms?
You will find many differing opinions on when to initiate breast cancer screenings with mammography. The American Cancer Society (ACS) suggests:
Women at average risk of breast cancer risk may start annual mammogram screening beginning at age 40
Women from ages 45-54 should be screened annually
Those over age 55 may continue with annual exams or every other year exams.
To further clarify, average risk denotes a woman without personal or family history of breast cancer, or a genetic mutation which increases risk of breast cancer. Women with higher than average risk may initiate breast cancer screening with mammography or other tools sooner than age 40.
The research was published in the American Medical Association Journal March 10.
When / how frequently to have screenings / Mammograms for breast cancer?
You can find several different views on when to start mammography tests for breast cancer. The American Society on Cancer (ACS) suggests:
Women at average risk of breast cancer may begin annual mammogram screening at age 40
Females between 45 and 54 years old should be screened annually
Those over 55 can proceed with annual or any other year's examinations.
To further explain, average risk denotes a woman without breast cancer history, personal or family background, or a genetic mutation that raises the risk of breast cancer. Women with a higher than average risk can soon initiate mammography or other tools for breast cancer screening
A small number of older women with breast cancer, a new study shows, may have genetic mutations that put them at risk for additional cancers , particularly ovarian cancer.
The researchers said that as many as one in 40 postmenopausal women with breast cancer before age 65 has a mutation in the BRCA1 or BRCA2 genes.
The researchers said that there is a mutation in the BRCA1 or BRCA2 genes in as many as one in 40 postmenopausal women with breast cancer before age 65.
Currently, the guidelines emphasize genetic testing in women who have a strong family history of these mutations. A well-publicized risk group is women of Ashkenazi Jewish descent. These women face about a 2.5 percent increased risk of having these mutations, study author Dr. Allison Kurian said.
The recommendations are now emphasizing genetic testing of people who have a deep family history of such mutations. Women of Ashkenazi Jewish origin are a well-publicised risk category. Such people face an increased risk of getting such mutations around 2.5 per cent, the author of the study Dr. Allison Kurian said.
"Most women survive breast cancer, and a healthy woman may live quite a while after breast cancer treatment. Could this person get breast cancer again? What about ovarian cancer? I think this risk should be discussed with them," Kurian said. She's an associate professor of medicine and epidemiology and population health at Stanford University, in California.
"Many women survive breast cancer, and after breast cancer treatment a healthy patient can live for quite a while. Will this person get breast cancer again? How about ovarian cancer? I think this possibility should be addressed with them," Kurian said. She is an associate professor at Stanford University, California, in medicine and epidemiology, and public health.
"We found the likelihood of carrying a BRCA mutation was about 2.5 percent in postmenopausal women diagnosed with breast cancer when they were under 65," she noted.
"In postmenopausal women diagnosed with breast cancer when they were under 65, we found the risk of having a BRCA mutation was around 2.5 per cent," she said.
When the investigators included older women diagnosed with breast cancer, there was a 3.5 percent risk of a BRCA or other mutation in the group.
If the study examined older women diagnosed with breast cancer, the population had a 3.5 per cent chance of BRCA or other mutation.
Funding was provided by Myriad Genetics, the Suzanne Pride Bryan Fund for Breast Cancer Research, the Jan Weimer Faculty Chair in Breast Oncology, and the BRCA Foundation. Myriad Genetics makes the genetic tests.
Myriad Genetics, the Suzanne Pride Bryan Breast Cancer Research Program, the Jan Weimer Faculty Chair of Breast Oncology and the BRCA Foundation provided funding. Myriad Genetics do the genetic research.
Kurian said in addition to family history, doctors often take age into account when deciding whether or not to suggest genetic testing.
In addition to family history, Kurian said doctors also take the age into consideration when determining whether to consider genetic testing or not.
The study included previously collected data on nearly 162,000 women between 1993 and 1998. The women were aged 50 to 79, and were from all over the United States.
Previously, the research contained data gathered on almost 162,000 women between 1993 and 1998. The women were between the ages of 50 and 79, and came from all over the USA.
From that larger group of women, the researchers compared nearly 2,200 women who were diagnosed with breast cancer to just over 2,300 women without the disease. The average age of women with a breast cancer diagnosis was 73.
The researchers compared approximately 2,200 women diagnosed with breast cancer to just over 2,300 women without the disease, from the broader group of people. The mean age of women diagnosed with breast cancer was 73.
In the whole breast cancer group, the researchers found a 3.5 percent genetic mutatlon rate. Just 1.3 percent of women without breast cancer had the genetic mutations, the findings showed.
The researchers found a genetic mutatlon prevalence of 3.5 per cent in the entire breast cancer population. The findings showed that only 1.3 per cent of women without breast cancer had the genetic mutations.
Only about one-third of the women who had breast cancer and were found to have BRCA mutations had been recommended for genetic testing. In the women without cancer, but who had a BRCA mutation, only one in five had been recommended by their doctor for genetic testing.
With genetic testing, only about one third of the women who had breast cancer and who were found to have BRCA mutations were recommended. Just one in five had been recommended by their doctor for genetic testing in the women without cancer but who had a BRCA mutation.
Robert Smith, the senior vice president for cancer screening at the American Cancer Society, said this was an interesting study that suggests there may be value in testing this older group of women who've already had breast cancer.
Robert Smith, the senior vice president at the American Cancer Society for cancer screening, said this was an interesting study that shows that there may be benefit in studying this older group of women who have already had breast cancer.
"The guideline-developing groups will look at this information to help inform their recommendations. This study will have to be put into context with other studies, but this data suggests this (genetic testing in postmenopausal women with breast cancer) is something to consider," Smith said.
"This research will be looked at by the guideline-developing organizations to better inform their guidelines, and will need to be placed into context with other studies, but this evidence indicates this (genetic testing of postmenopausal women with breast cancer) is something to consider," Smith said.
Kurian said the test isn't expensive.
She said the usual out-of-pocket cost for someone with insurance is about $100. For women without insurance, she said the cost is about $250 or less.
Kurian did not say the test was costly.
She said the average out-of-pocket expense is about $100 for those with insurance. She said the cost to women without insurance is about $250 or less.
The study was published March 10 in the Journal of the American Medical Association.
When/How Often to Get Breast Cancer Screenings/Mammograms?
You will find many differing opinions on when to initiate breast cancer screenings with mammography. The American Cancer Society (ACS) suggests:
Women at average risk of breast cancer risk may start annual mammogram screening beginning at age 40
Women from ages 45-54 should be screened annually
Those over age 55 may continue with annual exams or every other year exams.
To further clarify, average risk denotes a woman without personal or family history of breast cancer, or a genetic mutation which increases risk of breast cancer. Women with higher than average risk may initiate breast cancer screening with mammography or other tools sooner than age 40.
The research was published in the American Medical Association Journal March 10.
When / how frequently to have screenings / Mammograms for breast cancer?
You can find several different views on when to start mammography tests for breast cancer. The American Society on Cancer (ACS) suggests:
Women at average risk of breast cancer may begin annual mammogram screening at age 40
Females between 45 and 54 years old should be screened annually
Those over 55 can proceed with annual or any other year's examinations.
To further explain, average risk denotes a woman without breast cancer history, personal or family background, or a genetic mutation that raises the risk of breast cancer. Women with a higher than average risk can soon initiate mammography or other tools for breast cancer screening
Comments
Post a Comment